查詢結果分析
來源資料
相關文獻
- Treatment of Small Cell Lung Cancer--Ten Years' Experience at Taipei Veterans General Hospital
- Acute Lymphoblastic Leukemia in Young Adults: Two Chemotherapeutic Protocols for the Treatment of 46 Patients
- 小細胞型肺癌以鎝-99mMIBI胸部造影來評估化學治療反應與病人預後關係的初步報告
- Combination Versus Alternating Chemotherapy in Small-Cell Lung Cancer
- Cisplatin and 5-Fluorouracil as Neoadjuvant Chemotherapy: Predicting Response in Head and Neck Squamous Cell Cancer
- A Study on the Synergistic Effect of Whole-body Hyperthermia Treatment on Some Anticancer Agents in P-388 Lymphocytic Leukemia in CDF1 Mice
- 轉移性大腸直腸癌藥物治療的進展
- 輔助性中醫治療對於接受放射及化學治療之頭頸癌住院病人之效益
- 肺癌診治的迷思
- 輔助性中醫治療對於接受放射及化學治療之頭頸癌住院病人之效益
頁籤選單縮合
題名 | Treatment of Small Cell Lung Cancer--Ten Years' Experience at Taipei Veterans General Hospital=小細胞肺癌的治療--臺北榮總十年經驗 |
---|---|
作者姓名(中文) | 黃國良; 賴信良; 彭瑞鵬; |
作者姓名(外文) | Huang, Kuo-liang; Lai, Shinn-liang; Perng, Reury-perng; |
書刊名 | 胸腔醫學 |
卷期 | 17:4 2002.12[民91.12] |
頁次 | 頁364-371 |
分類號 | 416.224 |
語文 | eng |
關鍵詞 | 小細胞型肺癌; 化學治療; 存活期; 療效; Small cell lung cancer; Chemotherapy; Survival time; Response; |
中文摘要 | 肺癌高居國人癌症死因的第一位,其中小細胞型肺癌約佔肺癌病例的10-15%。小細胞型肺癌具有快速生長及早期轉移的特性。雖然對化學治療反應良好,但病患的中位數存活期卻比非小細胞癌差。本文統計了十年間在本院接受相同化學治療的小細胞型肺癌治療的結果,並探討影響結果的各項因素。 在研究期間,總共有211例(198例男性,13例女性)經細胞學或病理切片診斷為小細胞型肺癌的病患,接受cisplatin+VP-16 (PVP)的化學治療,視病情需要決定是否加作放射治療,病患生存時間以診斷為小細胞型肺癌至死亡或最後追蹤日期為止。 有33例(15.6%)達到complete response,100例(47.4%)達到partial response,27例(12.8%)為stable disease,51例(24.2%)為failure。病患的中位數生存期為9.8個月,其中擴散期病患為了7.4個月,侷限期病患為12.9個月。影響患者預後的因素包括疾病分期、患者活動力狀態及抽菸史。 回顧文獻,過去二十多年來雖然許多學者嘗試了各種化學治療方式,但病患整體的治療反應率及中位數存活期並沒有明顯的增加。以PVP為第一線的化學治療輔以放射治療,目前仍然是小細胞型肺癌的標準治療。如何增加反應率、延長存活期及減低治療的副作用仍需進一步研究。 |
英文摘要 | The purpose of this study was to evaluate the outcome of patients with small cell lung cancer (SCLC) treated at VGH-Taipei between July 1991 and December 2000, when cisplatin-based regimens were used. We retrospectively analyzed a series of 211 consecutive SCLC patients treated with standard chemotherapy using an etoposide/cisplatin (PVP) regimen combined with or without radiotherapy at a single institution during a 10-year period. Patients had a minimal follow-up of 1.2 years. Several pretreatment variables assessable in routine practice were analyzed for the treatment outcome comparison. The overall response rate was 63%, including a complete response in 15.6% of patients, a partial response in 47.4%, stationary disease in 12.8%, and progressive disease in 24.2% of patients. The significant favorable response factors were disease extent, performance status, and smoking status. The overall median survival time was 9.8 months, of which survival was 12.9 months in limited stage patients and 7.4 months in extensive stage patients, respectively. The significant favorable survival factors included disease extent, treatment response, performance status, and smoking status. Patients with limited stage SCLC given an etoposide/cisplatin regimen plus chest radiotherapy were significantly associated with prolonged survival. Disease extent, performance status, and smoking history had a significant influence on disease outcome. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。